| Name | Title | Contact Details |
|---|
OmniActive was born from Kancor Ingredients, an ingredient supplier rooted in the food and flavoring industry. Kancor has decades of experience extracting pure, quality ingredients from whole foods. With a history in extraction of natural products dating back to 1969, we at OmniActive are well versed in the technologies and processes necessary to provide specialized ingredients to the supplements space, as well as food and beverage companies. Kancor and OmniActive were both founded by the Mariwala family, with a long heritage in the spice industry. Patriarch Kanji Moorarji began trading in spices in 1857, an interest that continues to the present day. This history is reflected in the strength of our supply chain and raw material sourcing.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
We are passionate in our commitment to improving and renewing people`s lives. Sesen Bio is a late-stage company devWe are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company`s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.eloping fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body`s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium`s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors.
We are industry-leading experts in Bio Convergence. By combining the power of biology, engineering and computer science, we create the future of health. We extend the boundaries of what`s possible to give people better and healthier lives. Products from the BICO Group are trusted by more than 2,00 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 1800 publications. BICO is creating the future of health. Visit bico.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.